Literature DB >> 21242194

miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.

Huijuan Chai1, Min Liu, Ruiqing Tian, Xin Li, Hua Tang.   

Abstract

Chemotherapy is an important treatment for colorectal adenocarcinoma cancer; however, colorectal adenocarcinoma cells often develop resistance to chemotherapeutic drugs, leading to relapse and poor patient prognosis. The development of drug resistance is often a multifactor process, which involved several genes and cellular mechanisms. microRNAs are endogenous small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level. In the present study, we investigated the possible role of microRNAs in regulating drug sensitivity of colorectal adenocarcinoma cells SW620 and SW480. Using microRNA expression arrays and quantitative reverse transcriptase (RT)-PCR, we found that SW620 cells exhibited elevated miR-20a expression compared with SW480 cells. In addition, these two cell lines displayed different sensitivities to the chemotherapeutic drugs fluorouracil, oxaliplatin, and teniposide. Modulation of miR-20a altered the sensitivity of SW620 and SW480 cells to these drugs; knockdown of miR-20a sensitized SW620 cells to chemotherapeutic agents, whereas overexpression of miR-20a in SW480 cells resulted in chemoresistance. Endogenous BNIP2 mRNA and BNIP2 protein levels were inversely related to miR-20a levels as detected by quantitative RT-PCR and western blot analysis. Fluorescence reporter assays showed a direct interaction between miR-20a and the BNIP2 3'UTR. Taken together, our findings suggested that miR-20a may play a role in colorectal adenocarcinoma cancer cell drug resistance and may be a therapeutic target against chemotherapy drug resistance in colorectal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242194     DOI: 10.1093/abbs/gmq125

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  44 in total

Review 1.  The role of microRNAs in colorectal cancer.

Authors:  Aaron J Schetter; Hirokazu Okayama; Curtis C Harris
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

2.  The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer.

Authors:  Wang-Yang Chen; Xiao-Juan Zhao; Zhi-Fu Yu; Fu-Lan Hu; Yu-Peng Liu; Bin-Bin Cui; Xin-Shu Dong; Ya-Shuang Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

3.  MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma.

Authors:  Melanie Rammer; Gerald Webersinke; Sophie Haitchi-Petnehazy; Eva Maier; Hubert Hackl; Pornpimol Charoentong; Theodora Malli; Maria Steinmair; Andreas L Petzer; Holger Rumpold
Journal:  Clin Exp Metastasis       Date:  2017-11-13       Impact factor: 5.150

4.  miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.

Authors:  Hui Zhou; Changwei Lin; Yi Zhang; Xiuzhong Zhang; Chong Zhang; Pengbo Zhang; Xingwang Xie; Zeqiang Ren
Journal:  Cell Prolif       Date:  2017-02-19       Impact factor: 6.831

Review 5.  The emerging role of noncoding RNAs in colorectal cancer chemoresistance.

Authors:  Ling Wei; Xingwu Wang; Liyan Lv; Yan Zheng; Nasha Zhang; Ming Yang
Journal:  Cell Oncol (Dordr)       Date:  2019-07-29       Impact factor: 6.730

Review 6.  Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.

Authors:  María Antonia Lizarbe; Jorge Calle-Espinosa; Eva Fernández-Lizarbe; Sara Fernández-Lizarbe; Miguel Ángel Robles; Nieves Olmo; Javier Turnay
Journal:  Biomed Res Int       Date:  2017-05-10       Impact factor: 3.411

7.  miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB.

Authors:  Yiping Du; Mingxia Zhu; Xin Zhou; Zebo Huang; Jun Zhu; Jing Xu; Gongming Cheng; Yongqian Shu; Ping Liu; Wei Zhu; Tongshan Wang
Journal:  Tumour Biol       Date:  2015-08-20

Review 8.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 9.  An update on microRNAs as colorectal cancer biomarkers: where are we and what's next?

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Ajay Goel
Journal:  Expert Rev Mol Diagn       Date:  2014-08-28       Impact factor: 5.225

10.  High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

Authors:  Mads H Rasmussen; Niels F Jensen; Line S Tarpgaard; Camilla Qvortrup; Maria U Rømer; Jan Stenvang; Tine P Hansen; Lise L Christensen; Jan Lindebjerg; Flemming Hansen; Benny V Jensen; Torben F Hansen; Per Pfeiffer; Nils Brünner; Torben F Ørntoft; Claus L Andersen
Journal:  Mol Oncol       Date:  2013-02-28       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.